What Is Bleomycin Approved For? Label Indications, Per the Research

Bleomycin Is Administered by Specialists in a Clinical Setting

Bleomycin is a prescription medicine. It is not a self-administered product. In published practice it is prepared and given by oncology, pulmonology or critical care teams in hospitals, infusion centres and other supervised clinical settings, with monitoring that continues after each administration. Because of that, every question on this page about whether bleomycin is appropriate in a given situation has the same answer: that decision sits with the treating specialist team, and a person wanting to know whether a label indication applies to them should talk to your prescriber rather than rely on a summary page.

This page describes label indications only. It separates what regulators approved from what remains investigational, and it does not describe preparation, dilution, schedules or amounts, because those belong to the prescribing information held by the clinical team.

What Bleomycin Is Approved For

Bleomycin is classified among the antitumour (cytotoxic) antibiotics, a group of anticancer agents derived from microbial products and used within combination chemotherapy regimens, as summarised in a reference chapter on cytotoxic antibiotics (PMID 31643644). The United States prescribing information frames the oncology indications as palliative management, meaning the label describes use aimed at controlling disease rather than promising eradication.

The approved indication categories on the United States label are:

Two structural points follow from that table. First, the oncology indications are written at tumour-type level, and the label places bleomycin inside multi-agent treatment strategies rather than presenting it as a standalone therapy. Second, the pleural effusion indication is a different kind of use altogether: there the agent is used for its sclerosing effect on the pleural space rather than as systemic chemotherapy. Both remain specialist-administered.

Approval timing

Bleomycin has been a marketed prescription product in the United States since the 1970s, and the current label text for generic bleomycin for injection products is maintained through the standard regulatory process for older agents. Specific approval dates for individual manufacturers' products are published in regulatory listings rather than in the clinical literature, and this page does not restate dates that are not published in the sources cited here.

Uses That Are Investigational, Not Approved

Investigational is the correct word for any bleomycin use that falls outside the indication categories above. That includes laboratory and animal work, exploratory clinical applications in other tumour types, and any dermatologic or interventional use that is not listed on the label. Investigational status means a use has been studied or discussed in the literature, not that a regulator has reviewed and approved it, and not that it has been shown to be appropriate for any individual.

The distinction matters because bleomycin appears constantly in the published literature in a context that has nothing to do with treating cancer: it is the standard laboratory tool for inducing lung fibrosis in rodents. Papers with "bleomycin" in the title are frequently studying a different compound entirely, using bleomycin only to create the disease model. Reading such a paper as evidence about an approved bleomycin indication would be a category error.

Why Bleomycin Dominates the Fibrosis Research Literature

A methods review described the bleomycin model as the most widely used and best characterised animal model of pulmonary fibrosis, and researchers set out the procedures used to generate reproducible fibrotic lung injury in rodents for research purposes (PMID 28836192). In these experiments the compound under investigation is the candidate therapy, while bleomycin supplies the injury.

Examples across recent years illustrate the pattern, and all of them are preclinical:

• A 2025 nanoparticle study reported that inhalable small interfering RNA targeting interleukin 11 inhibited bleomycin-induced pulmonary fibrosis in animals (PMID 39791575).
• A 2025 cell engineering study reported that chimeric antigen receptor engineered cytolytic regulatory T cells reversed pulmonary fibrosis and remodelled the fibrotic niche with limited cytokine release syndrome in the model system used (PMID 40627450).
• A 2023 study reported that atractylodinol prevented pulmonary fibrosis by inhibiting recycling of transforming growth factor beta receptor 1 through stabilisation of vimentin (PMID 37641404).
• A 2025 study of glutathione reductase reported that GSR deficiency exacerbated oxidative stress and promoted pulmonary fibrosis (PMID 40723921).
• A 2022 drug delivery study reported that a nano-designed carbon monoxide donor ameliorated bleomycin-induced pulmonary fibrosis through macrophage manipulation (PMID 34864115).
• A 2022 formulation study described an inhaled deep eutectic solvent based nanoemulsion of pirfenidone evaluated in the context of idiopathic pulmonary fibrosis (PMID 36341935).
• A 2026 pharmacology study reported that zanubrutinib mitigated pulmonary fibrosis in aged mice by targeting the Wnt/beta-catenin signalling pathway (PMID 41110481).
• A 2022 study reported that CXCL4 drove fibrosis by promoting several key cellular and molecular processes (PMID 34986347), and a 2025 study reported that targeting PTGDS inhibited pro-inflammatory fibroblasts associated with skin fibrosis in systemic sclerosis (PMID 40478772).

None of those findings describe an approved use of bleomycin. They describe investigational candidates evaluated in systems where bleomycin was the injury agent. A reader searching for what bleomycin is approved for will encounter this literature in large volume; recognising its purpose prevents misreading it as indication evidence.

Safety Signals in the Published Literature: What Studies Report

The reason bleomycin became the standard fibrosis-inducing agent is itself a safety observation. The methods review noted that bleomycin produces lung injury progressing to fibrosis in laboratory animals, which is precisely why researchers adopted it to model human fibrotic lung disease (PMID 28836192). Preclinical reports using the model consistently described fibrotic remodelling of lung tissue after bleomycin exposure in rodents, including collagen accumulation and oxidative stress changes in one 2025 study (PMID 40723921) and macrophage-associated inflammatory changes in a 2022 study (PMID 34864115).

At class level, a reference chapter grouped bleomycin with other cytotoxic antibiotics used in cancer chemotherapy and summarised the liver injury profiles associated with that drug class (PMID 31643644). Full human safety information for bleomycin, including warnings, contraindications, monitoring requirements and cumulative exposure limits, is held in the prescribing information and is applied by the specialist team that administers the drug. This page does not reproduce that information and does not substitute for it.

Approved Versus Investigational: A Working Distinction

Reading an Indication Statement Carefully

Label indications are narrower than they look at first glance. Several features of the bleomycin label are worth noticing:

1. Palliative framing. The oncology indications are written as palliative management, which shapes the clinical goal described in the label.
2. Tumour histology, not symptom. The squamous cell carcinoma indication is defined by histology and anatomic site, not by a general category such as "skin lesions".
3. Combination context. Bleomycin is positioned within multi-agent chemotherapy approaches in the published literature on cytotoxic antibiotics (PMID 31643644), so indication statements do not imply monotherapy.
4. A non-oncology mechanism inside an oncology label. The pleural effusion indication relies on a sclerosing action in the pleural space, which is conceptually separate from systemic antitumour activity.

Questions That Belong With the Treating Clinician

Because bleomycin is specialist-administered, the questions readers most often have are clinical rather than informational. Whether a particular diagnosis falls inside a label indication, whether bleomycin is part of a given regimen, how lung function is monitored during treatment, what cumulative exposure limits apply, and what alternatives exist are all matters for the prescribing clinician and the wider oncology or pulmonology team. Published summaries such as this one can describe what the literature and the label say; they cannot evaluate an individual case.

This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing specialist team about any question involving bleomycin, its approved indications, or any investigational use.

Key Points

• Bleomycin is a prescription cytotoxic antibiotic given in hospital, infusion or critical care settings by specialist teams, never self-administered.
• Approved label indications cover palliative management of specified squamous cell carcinomas, Hodgkin and non-Hodgkin lymphomas and testicular carcinoma, plus use as a sclerosing agent for malignant pleural effusion.
• All other uses are investigational.
• Most published papers naming bleomycin use it to induce fibrosis in animals so that another candidate compound can be assessed, as described in a methods review of the model (PMID 28836192).
• Human safety details, monitoring and exposure limits live in the prescribing information and are applied by the treating team.

References

• Cytotoxic Antibiotics (LiverTox reference chapter, 2012)
• The Bleomycin Model of Pulmonary Fibrosis (Methods in Molecular Biology, 2017)
• Inhalable siRNA Targeting IL-11 Nanoparticles Significantly Inhibit Bleomycin-Induced Pulmonary Fibrosis (ACS Nano, 2025)
• CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS (JCI Insight, 2025)
• Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-beta receptor 1 recycling by stabilizing vimentin (Molecular Therapy, 2023)
• GSR Deficiency Exacerbates Oxidative Stress and Promotes Pulmonary Fibrosis (Biomolecules, 2025)
• Nano-designed CO donor ameliorates bleomycin-induced pulmonary fibrosis via macrophage manipulation (Journal of Controlled Release, 2022)
• Inhaled deep eutectic solvent based-nanoemulsion of pirfenidone in idiopathic pulmonary fibrosis (Journal of Controlled Release, 2022)
• Zanubrutinib mitigates pulmonary fibrosis in aged mice by targeting the Wnt/beta-catenin signaling pathway (Biochemical Pharmacology, 2026)
• CXCL4 drives fibrosis by promoting several key cellular and molecular processes (Cell Reports, 2022)
• Targeting PTGDS inhibits pro-inflammatory fibroblasts associated with skin fibrosis in systemic sclerosis (Rheumatology, 2025)